Digital therapeutics (DTx)
Also known as: DTx, digital therapeutic, prescription digital therapeutics
Digital therapeutics (DTx) are software programs, usually apps, that treat or manage a medical condition and are backed by clinical evidence, sometimes requiring regulatory approval and a prescription.
Examples include apps delivering cognitive behavioural therapy for insomnia or programs supporting addiction recovery. While DTx promised to make software a new kind of medicine, the industry learned painful lessons about getting doctors to prescribe apps and insurers to pay for them.
Digital therapeutics (DTx), explained at three levels
At home
Some apps don't just track your health; they're designed to treat a condition, like insomnia or anxiety, and have been tested in clinical studies just like medicines. These are called digital therapeutics.
At work
Digital therapeutics can deliver evidence-based treatment at scale, for example providing therapy programs to people who'd otherwise wait months for a specialist.
At home
Many DTx deliver structured programs, such as cognitive behavioural therapy lessons, with daily exercises and progress tracking. Some are used alongside medication, and some share progress with your care team.
At work
Depending on claims, DTx may be regulated as software as a medical device and require randomized controlled trials. Business models include prescription reimbursement, employer benefits, insurer contracts, and direct-to-consumer sales. Engagement over weeks is a key success factor.
At home
An app only works if you keep using it, and most people drop off health apps quickly. In my view, the hardest part of digital therapeutics isn't the science; it's designing something people stick with.
At work
Evaluate DTx on trial quality, comparators (versus usual care or a sham app), durability of effect, engagement data, privacy practices, and integration with clinical workflows. Public payers need health technology assessment frameworks that fit software. Germany's DiGA experience offers lessons on both access and pricing.
Real-world examples
At home
Carlos struggled with insomnia for years in Edmonton. His doctor recommended a clinically tested CBT-for-insomnia app. After six weeks of sleep exercises, he was falling asleep faster than he had in years.
At work
Lena is a benefits manager at a Canadian bank. She added a clinically validated digital therapy program for anxiety and insomnia to the employee benefits plan, giving staff faster access than traditional therapy waitlists.
Common confusions
- Any health or wellness app is a digital therapeutic. — DTx must treat or manage a condition with clinical evidence, often under regulatory oversight.
- Regulatory approval guarantees commercial success. — Without payers and prescribers on board, approved DTx have struggled, as Pear's bankruptcy showed.
- Digital therapeutics replace clinicians. — Most are designed to complement care, extending access rather than removing human support.
For analysts
If you're considering a DTx benefit, I'd look at completion rates as closely as trial results. A clinically proven program that employees abandon after week one won't deliver the outcomes in the brochure.
History & origin
Health apps exploded with smartphones in the late 2000s, but few had rigorous evidence. In 2017, the FDA cleared Pear Therapeutics' reSET, an app for substance use disorder, as the first prescription digital therapeutic. In 2020, the FDA authorized EndeavorRx, a video game for children with ADHD. Germany created a fast-track system in 2020, called DiGA, that lets doctors prescribe approved apps with public insurance coverage. But reimbursement in North America lagged, and Pear filed for bankruptcy in April 2023 despite having authorized products. Many companies shifted to employer or wellness models. In my opinion, Pear's failure showed that clinical evidence isn't enough: a treatment also needs a clear path to payment.